FGI-103

FGI-103

Systematic (IUPAC) name
2-[(E)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-3H-benzimidazole-5-carboximidamide
Clinical data
Legal status	Investigational New Drug
Identifiers
CAS Number	907169-69-1 Y
PubChem	CID: 5477931
ChemSpider	4585571
Chemical data
Formula	C19H16N6O
Molecular mass	344.369
SMILES n4c2cc(C(N)=N)ccc2nc4\C=C\c3cc1cc(C(=N)N)ccc1o3
InChI InChI=1S/C19H16N6O/c20-18(21)10-2-5-16-12(7-10)8-13(26-16)3-6-17-24-14-4-1-11(19(22)23)9-15(14)25-17/h1-9H,(H3,20,21)(H3,22,23)(H,24,25)/b6-3+ Key:OOKWWPFCCCMWIS-ZZXKWVIFSA-N

FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.

See also

• FGI-104
• FGI-106
• LJ-001